Daniel E. Abbott, MD, FACS

Associate Professor

  • Surgical Director, UW Health Liver and Pancreas Center
  • Division of Surgical Oncology

abbott@surgery.wisc.edu
Clinic: (608) 263-7502

  • Administrative Assistant: (608) 262-2025

600 Highland Avenue
Box 7375, Clinical Science Center
Madison, WI 53792

Education

  • MD, University of Washington School of Medicine, Seattle, Washington, 2003
  • General Surgery Residency, Northwestern University/Feinberg School of Medicine, Chicago, Illinois, 2010
  • Research Fellowship, Children's Memorial Research Center/Northwestern University, Division of Cancer Biology and Epigenomics, Chicago, Illinois, 2008
  • Surgical Oncology Fellowship, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2012

Clinical Specialties

Dr. Abbott is certified by the American Board of Surgery and is a Fellow of the American College of Surgeons. Trained specifically in cancer surgery at The University of Texas MD Anderson Cancer Center, his clinical focus is on gastrointestinal malignancies, as well as melanoma and sarcoma. He performs both traditional and laparoscopic resections for cancers of the liver, pancreas, and stomach. As Director of Cytoreductive and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Surgery, he is particularly interested in patients with peritoneal spread of appendiceal, colorectal and ovarian cancers. Dr. Abbott is active in a number of national organizations, including the Society of Surgical Oncology, the American Hepatopancreaticobiliary Association, the Association for Academic Surgery, and the Society of University Surgeons.

Research Interests

Dr. Abbott, a health services researcher, focuses on cost-effectiveness, systems efficiency, and socioeconomic disparity in cancer care. He is particularly interested in identifying opportunities to maintain or enhance cancer care using technology in a patient-centered manner and thereby helping patients access expert cancer care in more personalized settings.

Recent Publications

  • Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative.
    Gamboa AC, Lee RM, Turgeon MK, Zaidi MY, Kimbrough CW, Grotz TE, Leiting J, Fournier K, Lee AJ, Dineen SP, Powers BD, Veerapong J, Baumgartner JM, Clarke CN, Mogal H, Patel SH, Lee TC, Lambert LA, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Eng OS, Johnston FM, Greer J, Cloyd JM, Maithel SK, Staley CA
    Ann. Surg. Oncol. 2020 Jul 21;
    [PubMed ID: 32696303]

  • Early vs Late Readmissions in Pancreaticoduodenectomy Patients: Recognizing Comprehensive Episodic Cost to Help Guide Bundled Payment Plans and Hospital Resource Allocation.
    Acher AW, Barrett JR, Schwartz PB, Stahl C, Aiken T, Ronnekleiv-Kelly S, Minter RM, Leverson G, Weber S, Abbott DE
    J. Gastrointest. Surg. 2020 Jul 15;
    [PubMed ID: 32671797]

  • Predictors of Nonhome Discharge after Cytoreductive Surgery and HIPEC.
    Kubi B, Gunn J, Fackche N, Cloyd JM, Abdel-Misih S, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Dessureault S, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Patel SH, Dhar V, Lambert L, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Lee B, Maithel SK, Staley CA, Johnston FM, Wang NY, Greer JB
    J. Surg. Res. 2020 Jul 01; 255: 475-485
    [PubMed ID: 32622162]

  • Retroperitoneal sarcoma perioperative risk stratification: A United States Sarcoma Collaborative evaluation of the ACS-NSQIP risk calculator.
    Schwartz PB, Stahl CC, Ethun C, Marka N, Poultsides GA, Roggin KK, Fields RC, Howard JH, Clarke CN, Votanopoulos KI, Cardona K, Abbott DE
    J Surg Oncol 2020 Jun 17;
    [PubMed ID: 32557654]

  • Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors-There is hope, but more data are needed.
    Barrett JR, Abbott DE
    J Surg Oncol 2020 Sep; 122(3): 572
    [PubMed ID: 32419171]

All Publications on PubMed